Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Liabilities (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $15.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 103.63% to $15.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.8 million through Dec 2025, up 103.63% year-over-year, with the annual reading at $15.8 million for FY2025, 103.63% up from the prior year.
  • Other Non-Current Liabilities hit $15.8 million in Q4 2025 for Allogene Therapeutics, up from $15.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $15.8 million in Q4 2025 to a low of $2.8 million in Q1 2021.
  • Historically, Other Non-Current Liabilities has averaged $7.7 million across 5 years, with a median of $6.5 million in 2022.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 156.93% in 2022 and later fell 27.42% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $7.8 million in 2021, then decreased by 24.96% to $5.8 million in 2022, then decreased by 11.42% to $5.2 million in 2023, then surged by 49.86% to $7.8 million in 2024, then skyrocketed by 103.63% to $15.8 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ALLO at $15.8 million in Q4 2025, $15.5 million in Q3 2025, and $15.1 million in Q2 2025.